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Fe-deficiency anaemia is the most common cause of anaemia in developing countries. In these settings, many chronic infections, including tuber-
culosis (TB), are highly prevalent. Fe is an essential nutrient for both host and mycobacteria that play a pivotal role in host immunity and myco-
bacterial growth. A case–control study was performed in a TB-endemic region in Jakarta, Indonesia, among 378 pulmonary TB patients and 436
healthy controls from the same neighbourhood with the same socio-economic status. In a number of these subjects the Fe status could be explored.
The distribution of three polymorphisms in the natural resistance-associated macrophage protein gene (NRAMP1) including INT4, D543N and
30UTR was examined for a possible association with susceptibility to TB. Anaemia (corrected for sex) was present in 63·2 % of active TB com-
pared with 6·8 % of controls, with female patients more often affected. Anaemia was more pronounced in advanced TB as diagnosed by chest
radiography. Lower Hb concentrations in TB patients were accompanied by lower plasma Fe concentrations, lower Fe-binding capacity and
higher plasma ferritin. After successful TB therapy, Fe parameters improved towards control values and Hb levels normalised, even without
Fe supplementation. NRAMP1 gene polymorphisms were not associated with TB susceptibility, TB severity or anaemia. In conclusion, most
active TB patients had anaemia, which was probably due to inflammation and not to Fe deficiency since TB treatment without Fe supplementation
was sufficient to restore Hb concentration.
Tuberculosis: C-reactive protein: Anaemia: Iron: NRAMP1
Tuberculosis (TB), caused by Mycobacterium tuberculosis
(MTB), is a global health threat, with 8 million active new
cases and 2–3 million deaths annually. The majority of TB
cases reside in developing countries, among others in Indone-
sia, which harbours more than 10 % of TB cases worldwide1.
MTB is an intracellular pathogen that targets host phagocytes,
and consequently an effective host defence is required to coor-
dinate cellular immune response2. Following phagocytosis,
MTB lives within phagosomes of host macrophages and com-
petes with the host to acquire Fe in order to survive and repli-
cate3. For the host, Fe is an essential component of Hb, as Fe
binds and transports O2. Fe is also needed for electron trans-
port, DNA synthesis and immune function, for example, for
the formation of oxygen radicals4.
It remains unclear how MTB accumulates Fe in macrophages.
An excess of Fe supply will result inMTBgrowth, and Fe overload
is a known risk factor for infections, as this may worsen the dis-
ease. Fe overload, for example from dietary Fe, causes individuals
to be more susceptible to TB5. Interestingly, the MTB growth
within macrophages from individuals with hereditary haemochro-
matosis, a genetic disease which leads to Fe overload, is reduced6.
This can be explained by the fact that, even in severe Fe overload,
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macrophages in hereditary haemochromatosis provide an Fe-
deficient environment due to increased export of Fe from the
labile Fe pool to plasma by the export protein ferroportin7,8.
On the other hand, Fe deficiency can increase susceptibility
to various infectious diseases, since macrophages require Fe to
function well3. Even mild Fe deficiency causes a significant
impairment in the immune status and reduces the capacity to
control infections. Fe-deficiency anaemia is the most
common cause of nutritional deficiency anaemia in developing
countries, affecting mostly children and pregnant and lactating
women9. Therefore, Fe supplementation is often prescribed in
developing countries10.
Several susceptibility-associated genetic polymorphisms
have been proposed to explain differential susceptibility to
TB. Various studies have reported that subtle variations in
the natural resistance-associated macrophage protein gene
(NRAMP1) result in a higher risk for having TB11 – 13.
NRAMP1 is a metal transporter protein localised in late endo-
somal and lysosomal compartments, and probably plays an
important role in transferring diferric Fe across the phagosome
membrane14,15.
In the present study we conducted a case–control study in
Indonesia, a country with a high prevalence of both TB and
Fe-deficiency anaemia. Fe status of pulmonary TB patients
and controls was explored to determine the prevalence of
anaemia with or without Fe deficiency in active TB patients.
Also, the effect of TB infection on Fe status indicators during
the course of TB therapy was investigated, as inflammation
affects many indicators of Fe status16. Distribution of
NRAMP1 alleles and genotypes in Indonesia has not been
reported before. In the present study, three commonly inves-
tigated polymorphisms in the NRAMP1 gene, INT4, D543N
and 30UTR, were examined to explore whether such poly-




After written informed consent was obtained from all subjects,
494 newly detected sputum smear-positive pulmonary TB
patients aged over 15 years were recruited in a poor setting
area at an out-patient TB control clinic, Perkumpulan Pember-
antasan Tuberkulosis Indonesia (PPTI), in Jakarta from Janu-
ary 2002 until December 2005. This case–control study was
part of a larger TB study in Indonesia. The study design
was approved by the Medical Faculty University of Indonesia
and the Eijkman Institute Jakarta ethical committees. Pulmon-
ary TB was diagnosed based on the clinical presentation, chest
X-ray radiography (CXR), and confirmed by two consecutive
acid-fast bacilli-positive sputa. All patients were provided
with free anti-TB therapy according to the national TB pro-
gramme (2HRZE/4H3R3). Patients with seropositive HIV (n
7; 1·4 %), diabetes mellitus (n 96; 19·4 %), CHD (n 3;
0·6 %) or incomplete data (n 10; 2·0 %) were excluded from
the statistical analyses. For analysis after therapy, only
patients with complete medical records after TB therapy (n
153) were included.
In the same period, 519 healthy controls from the
neighbourhood where the cases lived, with the same
socio-economic status, were randomly selected and matched
for sex and age (^10 %). Controls were interviewed using
the same standardised questionnaire and underwent the
same physical and blood examination and CXR as cases.
Control subjects with CXR suspective of TB (n 17; 3·3 %)
or history of prior anti-TB treatment (n 7; 1·4 %), diabetes
mellitus (n 25; 4·8 %) and incomplete data (n 34; 6·5 %)
were excluded. Although not all control subjects were
tested for HIV status, since informed consent for HIV test-
ing in the control group could only be obtained later in the
study, HIV seropositivity was only found in two of 115
(1·7 %) tested controls. Indonesia has a low HIV prevalence
in the general population, which was similar to the number
found in TB patients and in accordance with earlier reports
for Indonesia1.
Blood samples were obtained by venepuncture. Full blood
counts were performed routinely in the clinic for all patients
before therapy and all controls using an automated blood ana-
lyser (Cell-Dyn 3200, Abbott Laboratories, Abbott Park, IL,
USA). Haematology data could be obtained only in sixty-
five of 153 patients after therapy since full blood counts are
not routinely performed in the clinical setting.
Plasma from heparinised blood was collected and stored at
2808C for further analysis. Fe status indicators including
plasma Fe, plasma Fe-binding capacity, Fe saturation and
plasma ferritin were measured from patients for whom haema-
tology data were available (n 65) and in a set of randomised
controls (n 76). Total plasma Fe was measured using an ascor-
bate/FerroZine colorimetric method (Abbott Laboratories,
Abbott Park, IL, USA). The plasma ferritin was measured
by a solid-phase, two-site chemiluminescent immunometric
assay (Immulite 2000; Diagnostic Product Corporation, Los
Angeles, CA, USA). Fe status indicators could, however,
only be measured in the plasma of thirty-three patients after
therapy due to limited plasma availability. Erythrocyte sedi-
mentation rate (ESR) and/or C-reactive protein (CRP) examin-
ation were measured as indicators of the inflammatory
response.
Genotyping of NRAMP1 single nucleotide polymorphisms
Genomic DNA was isolated from EDTA blood of patients
and controls. Two single nucleotide polymorphisms in the
gene NRAMP1, D543N (1703G . A in exon 15 leading to
an aspartate to asparagine substitution at codon 543) and
INT4 (a single nucleotide change in intron 4;
469 þ 14G . C), were analysed11. Multiplex assays were
designed using Assay Design software (Sequenom Inc.,
San Diego, CA, USA). Genotyping was performed using
the MassArray platform according to the manufacturer’s
protocols (Sequenom Inc.). In brief, after PCR on 2·5 ng
DNA a primer extension reaction was performed to intro-
duce mass differences between alleles and, after removing
salts by adding a resin, about 15 nl of the product was
spotted onto a target chip with 384 patches containing
matrix. Mass differences were detected using a Bruker Auto-
flex matrix-assisted laser desorption ionisation time-of-flight
(MALDI-TOF) mass spectrometer (Sequenom Inc., San
Diego, CA, USA) and genotypes were assigned real-time
using Typer 3.1 software (Sequenom Inc.). As quality
control, 10 % of samples were genotyped in duplicate and

















no inconsistencies were observed. Primer sequences are
available upon request.
Genotyping using fragment length analyses
PCR for a TGTG deletion polymorphism in the 30 untranslated
region (1729 þ 55del4), denoted as 30UTR, were performed
using 100 ng genomic DNA, 200mM of each dNTP, 10 pmol
of each primer, 50 mM-KCl, 10 mM-tri(hydroxymethyl)-ami-
nomethane-HCl (pH 9·0), 0·1 % Triton X-100, 1·5 mM-
MgCl2 and 0·5 U Taq DNA polymerase (Biolabs, Beverly,
MA, USA) in a total volume of 25ml. Forward primers
were 50-labelled with tetrachloro-6-carboxy-fluorescein (TET);
primer sequences and cycle conditions are available on request.
PCR products and a 400 HD-ROX size standard (Applied
Biosystems, Foster City, CA, USA) in HiDi formamide were
run on an ABI Prism 3700 DNA Analyzer (Applied Biosystems),
and results were analysed using GeneScan Analysis and
Genotyper software (Applied Biosystems). Several homozygous
alleles were sequenced to verify allele lengths.
Statistical analysis
Data from the questionnaires, physical examinations, labora-
tory analyses and genotypings were analysed using SPSS
version 12.0 (SPSS Inc., Chicago, IL, USA). Data were
checked for normality using the Kolmogorov–Smirnov test.
Independent and paired t tests were used to compare means.
Ferritin concentrations were transformed to natural logarithms
to obtain normality. Analysis of covariance was used to com-
pare indicators of Fe status.
The Hardy–Weinberg equilibrium of each polymorphism
was checked using the program HWE17. The program CONT-
ING was used to calculate x2 and associated values for a con-
tingency table17. All statistical analyses were two-sided and P
values ,0·05 were considered as statistically significant.
Results
A total number of 378 newly detected sputum-positive pul-
monary TB patients (median age 29 (range 15–67) years)
and 436 community healthy controls (median age 33 (range
15–70) years) were included. Clinical characteristics of all
included TB patients and controls are presented in Table 1.
In active TB, CRP concentrations and ESR were both elevated
and correlated highly in the active TB patients at recruitment
(Spearman’s rank r 0·52; P,0·001). Both CRP concentrations
and ESR returned to normal levels after successful TB therapy
(paired t test).
Table 1. Clinical characteristics of pulmonary tuberculosis (TB) patients before and after TB therapy
compared with healthy community controls*








Mean SD Mean SD Mean SD
Males (n) 225 82 245
Females (n) 153 71 191
BMI (kg/m2) 17·6 2·7 19·7 2·6 22·6 4·5
Inflammatory indicators
ESR (mm/h) 84·0 32·8 18·2 16·2 17·2 13·5
CRP (mg/l) 62·6† 43·5 7·7 8·9 6·6‡ 15·9
Haematological indicators
Anaemia (n)§ 239 5k 30
Anaemia (%)§ 63·2 7·6k 6·8
Hb (g/l){ 119 17 139k 15 142 20
MCV (fl) 76·9 8·1 82·2k 7·2 84·4 6·5
MCH (pg) 25·9 4·4 28·1k 2·7 28·8 2·5
Fe status indicators
Ferritin (mmol/l){ 313·7k 289·7 71·9** 90·1 97·9†† 65·6
Serum Fe (mmol/l) 8·2k 5·3 16·0** 6·5 16·8†† 5·8
Fe saturation (%) 19·6k 13·4 32·3** 15·8 30·1†† 11·1
Fe-binding capacity (mmol/l) 42·8k 10·1 52·4** 11·2 56·7†† 8·6
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; MCV, mean corpuscular volume; MCH, mean corpus-
cular Hb.
* All values before TB therapy were significantly different compared with controls (t test). All values before TB
therapy were also increased or decreased significantly (P,0·05) at the end of the therapy (paired t test, tested
only in individuals with two time points).
† Data were collected from 240 individuals.
‡ Data were collected from 295 individuals.
§ Criteria for anaemia: males Hb , 130, females Hb , 120 g/l.
kData were collected from sixty-five individuals.
{Male and female values were taken together.
** Data were collected from thirty-three individuals.
†† Data were collected from seventy-six individuals.

















Anaemia in active tuberculosis and its association with
clinical presentation
Active TB was a strong predictor of lower Hb concentrations.
In the patients, Hb concentrations were significantly correlated
to CRP concentrations (P¼0·013), but not to ferritin concen-
tration (P.0·2; analysis of covariance controlling for age
and sex). Anaemia was found in 239 active TB patients
(63·2 %) compared with only thirty controls (6·8 %). Females
were more often affected by anaemia than males, both
among TB patients (74·5 v. 55·6 %) and among controls
(10·9 v. 3·6 %). At the end of successful TB therapy, anaemia
had been corrected without any Fe therapy or dietary sup-
plementation in almost all patients. Hb concentrations were
20 g/l higher after treatment (paired t test; P,0·001). The
increase of Hb concentrations between recruitment and end
of TB treatment was associated with a decrease of the inflam-
matory indicators such as ESR and CRP. Also mean corpuscu-
lar volume (MCV) of erythrocytes and mean corpuscular Hb
(MCH) levels increased (Table 1). Only five patients (7·6 %
of sixty-five measured post-therapy) remained anaemic but
their Hb concentrations increased significantly.
TB patients had coughing (98 %) as their main complaint.
As TB is a chronic disease, the duration of the main complaint
before TB patients presented themselves in the clinic might be
of importance. Anaemia was more prevalent in TB patients
with coughing for more than 1 month as compared with
patients with a recent complaint (, 1 month) (P¼0·041;
data not shown), probably reflecting long-term effects of
immune activation on Hb concentrations16. Blood coughing
was present in 46 % of the cases. Although a trend could be
observed, there was no significant correlation between occur-
rence of anaemia and blood coughing (P¼0·054) (Table 2).
Furthermore, anaemia was present more frequently in
advanced TB (ninety-two of 118 known CXR results;
77·9 %) compared with mild or moderate TB (forty-eight of
eighty-eight cases; 54·5 %) (P,0·001) as assessed by CXR
abnormalities (Table 2). CXR abnormalities were classified
as mild or moderate TB (n 88) or advanced TB (n 118),
based on the extent of lesions on CXR as described else-
where18. Anaemia was also negatively associated with smok-
ing habits. TB patients who were currently smoking or had
ever smoked in the past (designated as ‘ever’) were surpris-
ingly less frequently anaemic compared with those who
never smoked (P¼0·003) (Table 2). In a more extended
study in our group we found that smoking was not associated
with TB (OR 0·99 (95 % CI 0·76, 1·31); data not shown)
Anaemia also affected thirty-one control individuals, con-
sisting of twenty-two females (10·0 %) and nine males
(5·7 %). Of the female controls with low Hb (69–118 g/l),
eleven individuals had a very low MCV (48·6–76·0 fl), and
in the male controls with low Hb (103–128 g/l), seven individ-
uals had a very low MCV (59·1–69·3 fl), suggesting that these
individuals may have anaemia with Fe deficiency. Further-
more, nine males of the control group had a normal Hb
(133–174 g/l) with a very low MCV (58·5–75·7 fl) and six
females had a normal Hb (124–140 g/l) with a low MCV
(60·4–74·1 fl), which could be related to thalassaemia minor.
Thalassaemia (especially minor) must be considered in the
differential diagnosis of normal Hb with a low MCV value.
Follow up of thirty-three tuberculosis patients: iron status
indicators and anaemia
The Fe status indicators were measured in plasma for the base-
line data in a random set of active TB patients before therapy
(n 65) and after therapy (n 33), and compared with controls,
matched for sex and age (n 76). Many indicators of Fe status
were influenced by the inflammatory response. In patients with
active TB, plasma Fe concentrations and Fe saturation were
lower, whereas ferritin concentration was increased as com-
pared with controls. As was to be expected, there was a
strong correlation between these indicators of Fe status and
CRP concentrations. Linear regression analysis showed a cor-
relation between ferritin and CRP concentrations (R 2 0·19;
P,0·001) with an unadjusted coefficient of 2·9, meaning
that for every 10 g/l increase in CRP concentration, ferritin
concentration had increased by almost 30mg/l. Moreover, at
the end of TB therapy, all Fe indicators had returned to
normal values with disappearance of the inflammatory
response as indicated by normal concentrations of CRP and
a normal ESR (Table 1). At the end of successful TB therapy,
anaemia without Fe deficiency (ferritin concentrations
.12mg/l) was found in three patients (all males, Hb range
119–129 g/l, CRP all ,5 g/l). One of those anaemic patients
had a very low MCV and MCH value (Hb 128 g/l, MCV
60·2 fl, MCH 20·8 pg), which may suggest thalassaemia
minor. On the other hand, Fe deficiency was observed in
three female patients who were, however, not anaemic.
In the control group, three anaemic individuals (all female)
showed a normal plasma ferritin level (35–130mg/l). One of
these controls had very low MCV and MCH values (Hb
118 g/l, MCV 63·4 fl, MCH 22·1 pg), again suggesting thalas-
saemia minor. A plasma ferritin value #12mg/l was observed
in one female control with a normal Hb value (122 g/l).
Table 2. Anaemia status of active pulmonary tuberculosis (TB) patients
in relation to clinical signs or symptoms
(Frequency and percentage frequency)
Non-
anaemics* Anaemics*
n % n % P
Coughing blood
No 66 17·6 138 36·5 0·054
Yes 73 19·3 101 26·7
Chest X-ray†
Mild or moderate TB 40 19·4 48 23·3 ,0·001
Advanced TB 26 12·6 92 44·7
BMI
No wasting ($ 18·5 kg/m2) 62 16·4 59 15·6 ,0·001‡
Mild wasting
(17 to , 18·5 kg/m2)
37 9·80 50 13·2
Moderate wasting
(16 to , 17·0 kg/m2)
19 5·0 50 13·2
Severe wasting
(, 16·0 kg/m2)
21 5·6 80 21·2
Smoking
Ever 96 25·5 128 33·9 0·003
Never 43 11·4 111 29·4
* Criteria for anaemia: males Hb , 130, females Hb , 120 g/l.
† A chest X-ray was assessed in 206 patients.
‡ Subjects with BMI , 18·5 kg/m2 were pooled as the wasting group and compared
with the no wasting group (x2 test).

















NRAMP1 gene polymorphisms and susceptibility to
tuberculosis
In the Indonesian population, the INT4 polymorphism proved
to be rare and was not further analysed. The genotypes of the
NRAMP1 D543N and the 30UTR polymorphisms were in
Hardy–Weinberg equilibrium in the total group of individuals
as well as in the healthy controls and patients. No significant
differences could be observed between healthy controls and
TB patients, suggesting that NRAMP1 polymorphisms in our
population are not associated with TB susceptibility. The dis-
tribution of the alleles and genotypes of the NRAMP1 poly-
morphisms in the Indonesian population is presented in
Table 3. Furthermore, NRAMP1 polymorphisms are not
associated with TB severity, as evidenced by CXR, or by
anaemia in active TB (data not shown).
Discussion
Fe-deficiency anaemia has been reported in many developing
countries19,20. In these countries many chronic infectious dis-
eases are present at high rates, including pulmonary TB. The
prevalence of anaemia in our healthy control group, living in a
poor and TB-endemic area, was surprisingly low (6·7 %),
females being more affected than males. In the present study
children aged less than 15 years and pregnant women, individ-
uals at high risk of anaemia, were not included. Like others we
observed that in developing countries Fe deficiency is becom-
ing a less important cause of anaemia compared with infec-
tion21,22.
It is well known that most patients with active pulmonary
TB have anaemia23 – 25, but the precise mechanism remains
unclear. Blood loss in the sputum (haemoptysis) has been
mentioned in textbooks as one of the causes. However, original
studies were never performed and haemoptysis was not associ-
ated with anaemia in the present study population. Furthermore,
deficiencies of Fe and other nutrients, caused by loss of appetite
and fever, are associated with a low BMI24,26,27.
Anaemia of chronic disease (ACD), also in active TB, is
associated with a low serum Fe, Fe saturation and Fe-binding
capacity, and with a high serum ferritin5,28, while in uncompli-
cated Fe deficiency serum ferritin is always low29. During
inflammation ferritin, being an acute-phase reactant, is
increased. Hence, the presence of inflammation in ACD can
be estimated by increased concentrations of acute-phase pro-
tein such as CRP or by ESR16,24. In our population of TB
patients, anaemia was mostly due to ACD and not to Fe
deficiency, as shown by the comparison of haematological
and Fe parameters within the same patients before and at 6
months after TB therapy, as these subjects received no Fe
treatment. In ACD the decrease of Fe in the plasma compart-
ment and the increase of ferritin, mainly in macrophages, is
due to cytokine-mediated up regulation of ferritin, and
reduced Fe export due to increased hepcidin production30.
All such modifications in Fe status may be a protective
response against the invading microbes4,31.
As the patients in the present study did not receive Fe sup-
plementation, an increase of the Hb concentration over 6
months is mainly due to the normalisation of the inflammatory
response. Alternatively, the increase of Hb concentration
could be influenced by a better nutrition and a better appetite;
patients gained weight as evidenced by a higher BMI after
successful TB therapy26. Fe supplementation in developing
countries, where Fe deficiency is highly prevalent, should
therefore not be routinely prescribed when Fe status is
unknown, as this may exacerbate infection, not only TB32,
but also malaria33 or helminth infection34. In children living
in malaria endemic areas, Fe supplementation appears to
have beneficial effects in Fe-deficient children, but harmful
effects in Fe-replete children35. In contrast, a study in
Malawi reported that Fe supplementation in developing
countries with a high prevalence of both HIV infection and
Fe deficiency is not contraindicated36. Fe is believed to
Table 3. Distribution of NRAMP1 alleles and genotypes*







Polymorphism n % n % P
INT4 G 419 99·3 704 97·8 n.a.
(469þ14G . C) C 3 0·7 16 2·2
D543N G 334 81·5 546 78·0 0·17
(1627G . A) A 76 18·5 154 22·0
GG 136 66·3 217 62·0 0·33†
GA 62 30·2 112 32·0
AA 7 3·4 21 6·0
30UTR TGTG þ 348 81·3 568 78·2 0·21
TGTG del 80 16·7 158 21·8
TGTG þ /þ 141 65·9 226 62·3 0·35‡
TGTG þ /del 66 30·8 116 32·0
TGTG del/del 7 3·3 21 5·8
n.a., Not analysed.
* No significant differences were observed in the distribution of NRAMP1 single nucleotide polymorph-
ism alleles or genotypes between tuberculosis patients and healthy controls (x2 tests).
† Genotype GA and AA combined for analysis.
‡ Genotype TGTG þ /del and TGTG del/del combined for analysis.

















enhance the activity of the pyrazionic acid-containing first-line
TB drug pyrazinamide37. The conclusion that some patients
with pulmonary TB and mild to moderate anaemia may ben-
efit from Fe supplementation22 has no practical implication
since Fe treatment of TB patients only caused a minimal
increase of Hb after the first month, which disappeared after
the second month of treatment. In contrast, in Fe-overload
patients, Fe chelators may become important drugs for treat-
ment of malaria, TB and HIV, to deprive micro-organisms
from Fe as an essential nutrient4,38. Fe chelators added to
TB therapy should only be given to known overload patients
as it may impair the host defence, and reliable investigations
are not available39.
The only effective treatment for ACD is, thus, to cure the
underlying disease. Individuals in the present study with a
very low MCV and only mild anaemia may have had thalas-
saemia minor. Haemoglobinopathies, present in 0·1–10 % of
individuals of various ethnic groups in Indonesia40,41, may
be underdiagnosed42. The risk of these individuals developing
TB, however, needs to be further investigated.
Macrophages have several strategies to acquire Fe from
their specific environment, including erythrophagocytosis
and uptake of transferrin-bound Fe, non-transferrin-bound
Fe, haem and Hb. Fe is needed for both host defence and sur-
vival of the pathogen4. There is a constant competition
between host and microbes for this essential but toxic element.
It remains unclear which role NRAMP1 plays in the patho-
genesis of TB, being a metal transporter that resides in the
phagosome membrane14. Atkinson & Barton43 showed that
NRAMP1 has a function in Fe efflux from phagosome to cyo-
tosol43, while others found that it promotes the influx of Fe
into the phagosome44. In a recently published meta-analysis
of the influence on TB susceptibility of the four most fre-
quently studied NRAMP1 polymorphisms45 including INT4,
D543N and the 30UTR, it was shown that a large difference
between populations can be observed. In Europeans none of
the polymorphisms were associated with TB13. In Africans
three of the four polymorphisms (not the 30UTR variant)
were associated with TB11 and in Asians also three out of
four polymorphisms (not the INT4 variant) were associated
with TB46,47. A striking difference between the present
study and the other studies in Asian populations is that the
allele frequencies of the polymorphisms are very different.
We find the C allele of the INT4 polymorphism in only 2 %
of our controls while this is found in 14 % of Japanese and
21 % of Chinese controls. We find the 30UTR deletion allele
in 22 % of our controls while this is found in 8–19 % in
five other Asian populations. Similarly we find the A allele
of the D543N polymorphism in 22 % of our controls while
this is found in 2–15 % of six other Asian populations. It
appears that not only the association of TB with NRAMP1
polymorphisms is different between continents but also the
distribution of alleles is also very different between Asian
populations, which may reflect a difference in selective press-
ure in the past. If the NRAMP1 polymorphisms studied here
are functional polymorphisms influencing TB susceptibility
directly, we should have observed a similar association. If
these polymorphisms are, however, merely in linkage disequi-
librium with a functional variant elsewhere in NRAMP1 (or a
neighbouring gene) the association between certain alleles and
TB susceptibility can vary greatly between populations as has
been shown by Li et al.45. Further studies into other variations
in NRAMP1 or in other genes involved in susceptibility to TB
are needed.
To conclude, the present results support earlier observations
that anaemia in active TB is mainly the result of ACD, more
than of Fe deficiency. As the Hb concentration increased after
successful TB therapy, Fe supplementation was not necessary.
Fe supplementation in developing countries should be
restricted to children and women of reproductive age, who
have the highest prevalence of Fe deficiency.
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